Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Egito Association in Type 2 Diabetes and Hypertension
NCT04970108Phase 3Withdrawn
- Sponsor
- EMS
- Start
- Aug 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, triple-blind trial of Empagliflozin + telmisartan in type 2 diabetes mellitus (T2DM) and hypertension (HTN) (2 arms), sponsored by EMS. Primary endpoints: Glycated hemoglobin at 120 days and Systolic blood pressure at 120 days. Planned start Aug 2023; status: withdrawn.
02
Drugs
Empagliflozin + telmisartan
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on NCT04970108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04970108.